LamKap Bio beta AG
Biotechnology, pharmaceutical research and developmentPharmaceutical and biotechnology companies (licensing) and cancer patients (via clinical therapies)
LamKap Bio beta AG is a Swiss AG registered in Freienbach, SZ. Its registered activity falls under Medical laboratory activities.
AI-enriched data· marks AI-enriched fields
AI Insight
Registry narrative generated from SHAB/SOGC facts.
Officers4Active Relations3Deleted Relations0SOGC Records6First Record12.12.2017Latest Activity14.08.2025BiotechnologyOncologyBispecific AntibodiesAntibody TherapeuticsSwiss BiotechR&D
Registry Information
Renamed 2×
Formerly: LamKap Bio AG · (LamKap Bio Ltd) (LamKap Bio SA)
- Swiss UID
- CHE-446.791.526
- Legal Name
- LamKap Bio beta AG
- Legal Form
- Limited or Corporation
- Incorporated
- 12 Dec 2017
- Share Capital
- CHF 100'000.00
- Canton
- SZ
- Status
- Active
- Country
- Switzerland
Company Purpose
Translating…
NOGA Codes
(Industry classification)Medical laboratory activities
RHUMAN HEALTH AND SOCIAL WORK ACTIVITIES86Human health activities869Other human health activities8691Diagnostic imaging services and medical laboratory activities869102
Industry Health
Registered Address
Bahnhofstrasse 1
8808, Pfäffikon SZ, SZ
Companies at this address
Enrich from integrations
Pull data from your connected providers and merge it with the registry.
Registry Pulse
Registry pulse is a Pro feature
Current Directors & Officers
From the web
Target Customers
Pharmaceutical and biotechnology companies (licensing) and cancer patients (via clinical therapies)
Competitors (1)
LamKap Bio alpha AG, LamKap Bio gamma AG
LamKap Bio alpha AG and LamKap Bio gamma AG are affiliated entities within the same group, focusing on independent bispecific antibody projects.
Sources (7)
LamKap Bio Group and Lonza Collaborate to
lamkapbio.com
LamKap Bio – a Group of 3 companies
lamkapbio.com
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
pmc.ncbi.nlm.nih.gov
Our Pipeline
lightchainbio.com
shab.ch
shab.ch
SHAB Entries · Mercury-Reports
mercury-reports.com
Frontiers | Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
frontiersin.org